Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis
Renal amyloidosis is a complication of ankylosing spondylitis. A possible pathogenetic role is due to TNF-α, with a direct action on glomerular receptors TNFR2 and renal injury, secondary to deposition of amyloid fibrils. The most frequent clinical manifestation is proteinuria or nephrotic syndrome....
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-09-01
|
Series: | Reumatismo |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/334 |
id |
doaj-39b93040f03d4423b3318963ac393d68 |
---|---|
record_format |
Article |
spelling |
doaj-39b93040f03d4423b3318963ac393d682020-11-24T23:06:31ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-09-0159324024310.4081/reumatismo.2007.240Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitisA. GalloM.G. FerrucciS. BellissimoS. StisiRenal amyloidosis is a complication of ankylosing spondylitis. A possible pathogenetic role is due to TNF-α, with a direct action on glomerular receptors TNFR2 and renal injury, secondary to deposition of amyloid fibrils. The most frequent clinical manifestation is proteinuria or nephrotic syndrome. Etanercept, a soluble receptor of TNF-α, binds this circulant cytokine with a progressive improvement of renal function and reduction of deposits of amyloid. Transient leukopenia, observed during ankylosing spondylitis, should not be considered a controindication to the use of Etanercept, but it requires a constant monitoring. The benefit observed in our patient can represent an indication to the use of Etanercept for the management of amyloidosis.http://www.reumatismo.org/index.php/reuma/article/view/334 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
A. Gallo M.G. Ferrucci S. Bellissimo S. Stisi |
spellingShingle |
A. Gallo M.G. Ferrucci S. Bellissimo S. Stisi Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis Reumatismo |
author_facet |
A. Gallo M.G. Ferrucci S. Bellissimo S. Stisi |
author_sort |
A. Gallo |
title |
Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis |
title_short |
Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis |
title_full |
Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis |
title_fullStr |
Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis |
title_full_unstemmed |
Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis |
title_sort |
response to anti-tnf-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis |
publisher |
PAGEPress Publications |
series |
Reumatismo |
issn |
0048-7449 2240-2683 |
publishDate |
2011-09-01 |
description |
Renal amyloidosis is a complication of ankylosing spondylitis. A possible pathogenetic role is due to TNF-α, with a direct action on glomerular receptors TNFR2 and renal injury, secondary to deposition of amyloid fibrils. The most frequent clinical manifestation is proteinuria or nephrotic syndrome. Etanercept, a soluble receptor of TNF-α, binds this circulant cytokine with a progressive improvement of renal function and reduction of deposits of amyloid. Transient leukopenia, observed during ankylosing spondylitis, should not be considered a controindication to the use of Etanercept, but it requires a constant monitoring. The benefit observed in our patient can represent an indication to the use of Etanercept for the management of amyloidosis. |
url |
http://www.reumatismo.org/index.php/reuma/article/view/334 |
work_keys_str_mv |
AT agallo responsetoantitnfatreatmentforsecondaryrenalamyloidosisinapatientwithankylosingspondylitis AT mgferrucci responsetoantitnfatreatmentforsecondaryrenalamyloidosisinapatientwithankylosingspondylitis AT sbellissimo responsetoantitnfatreatmentforsecondaryrenalamyloidosisinapatientwithankylosingspondylitis AT sstisi responsetoantitnfatreatmentforsecondaryrenalamyloidosisinapatientwithankylosingspondylitis |
_version_ |
1725622599064485888 |